Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Study Purpose

The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to Temozolomide increases the activity of chemotherapy.The primary objective of the study is the best response (Complete Response or Partial Response) while trial treatment, within 18 or 24 weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints are assessing the side effects, the length of time before progression (Progression Free Survival) and overall survival (OS). This trial will address two important questions:

  • - does targeting blood vessel development using bevacizumab, (a monoclonal antibody against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour when used with existing chemotherapy, compared to the effect of the existing chemotherapy alone (temozolomide)? NOTE- This question has been completed.
  • - does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the effect on a tumour compared to the effect of one alone (temozolomide) NOTE - This question has been completed.
  • - does the addition of dinutuximab beta added to a backbone chemotherapy (temozolomide or temozolomide + topotecan) increase the effect of backbone alone.
Patients aged 1-21 years of age with relapsed or refractory high-risk neuroblastoma are randomised to one of two treatment arms: temozolomide-topotecan (TTo) or dinutuximab beta-temozolomide-topotecan (dBTTo). Temozolomide (T), irinotecan-temozolomide (IT), bevacizumab-T (BT), BIT (bevacizumab-IT), bevacizumab-temozolomide-topotecan (BTTo) and dinutuximab beta-temozolomide (dBT) are now closed to recruitment.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 1 Year - 21 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria

  • - Histologically proven neuroblastoma as per International Neuroblastoma Staging System (INSS) definition - Relapsed: any relapsed or progressed high-risk neuroblastoma - Refractory high risk disease: Lack of adequate response to frontline therapy that precludes the patient from proceeding to consolidation therapies - Measurable disease by cross sectional imaging (RECIST) or evaluable disease - Age ≥1 to ≤21 years - Informed consent from patient, parent or guardian - Performance Status:Lansky ≥ 50%, Karnofsky ≥ 50% or Eastern Cooperative Oncology Group ≤3 (Patients who are unable to walk because of paralysis, but who are able to sit upright unassisted in a wheelchair, will be considered ambulatory for the purpose of assessing performance score) - Life expectancy of ≥12 weeks - No bone marrow disease: Platelets ≥75 x 10^9/L (unsupported for 72 hours), absolute neutrophil count ≥0.75 x10^9/L (no G-cerebrospinal fluid support for 72 hours), Haemoglobin ≥8 g/dL (transfusions allowed) Bone marrow disease: Platelets ≥50 x10^9/L (unsupported for 72 hours), absolute neutrophil count (ANC) ≥0.5 x 10^9/L (no granulocyte colony stimulating factor (G-CSF) for 72 hours), Haemoglobin ≥8 g/dL (transfusions allowed) - Renal function (within 72 hours of eligibility assessment): Absence of clinically significant proteinuria (early morning urine dipstick <2+).
When the dipstick urinalysis shows a proteinuria ≥2+, a protein:creatinine (Pr/Cr) ratio must be <0.5 or a 24 hour protein excretion must be <0.5g
  • - Serum creatinine ≤ 1.5 upper limit of normal for age, if higher, a calculated glomerular filtration rate (radioisotope) must be ≥60 ml/min/1.73 m2 - Liver function (within 72 hours of eligibility assessment): aspartate aminotransferase (AST) or Alanine Aminotransferase (ALT) ≤2.5 ULN and Total bilirubin ≤1.5 upper limit of normal (ULN).
In case of liver metastases, AST or ALT ≤5 ULN and Total bilirubin ≤2.5 ULN
  • - Cardiac function, shortening fraction ≥29% on echocardiogram - Coagulation, patients not on anticoagulation must have an international normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 ULN for age.
Anti-coagulation is permitted as long as the INR or APTT is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants for at least two weeks at the time of study enrolment
  • - Blood pressure below 95th centile for age and sex.
Use of antihypertensive medication is permitted
  • - Males or females of reproductive potential may not participate unless they agree to use an effective contraceptive method, for the duration of study therapy and for up to 6 months after the last dose of trial drugs.
A negative urine pregnancy test must be obtained within 72 hours prior to dosing in females who are post-menarche - No dyspnoea at rest and pulse oximetry > 94% in room air - Availability and willingness to place a double central venous access if needed for trial treatment and supportive care in case of treatment with chemo-immunotherapy

Exclusion Criteria:

- Previous treatment with bevacizumab, temozolomide, irinotecan or any combination of these drugs - Known hypersensitivity to: Any study drug or component of the formulation, Chinese hamster ovary products or other recombinant human or humanised antibodies, Dacarbazine - Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular accident, peripheral arterial thrombosis) - Any ongoing arterial thrombo-embolic events - Patient less than (at point of planned date of randomisation): 48 hours post bone marrow aspirate/trephine, 48 hours post central line insertion, Four weeks post major surgery, One week post core biopsy, Two weeks from prior chemotherapy, Six weeks from prior craniospinal radiotherapy or MIBG therapy and two weeks from radiotherapy to the tumour bed, Eight weeks from prior myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell transplant), Three months from prior allogeneic stem cell transplant, 14 days or 5 half-lives (whichever occurs later) from last administration of an IMP in an IMP-trial, 6 months from presentation of lung haemorrhage/haemoptysis - Bleeding metastases (patients with CNS metastases can be enrolled as long as the metastases are not bleeding) - Invasion of major blood vessels - Use of enzyme inducing anticonvulsants within 72 hours of randomisation - History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e. in the absence of therapeutic anticoagulation) - History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to study enrolment - Current chronic intestinal inflammatory disease/bowel obstruction - Intolerance to galactose and fructose, lactase deficiency, and/or defect of absorption of galactose and fructose - Pregnant or lactating patient - Any uncontrolled medical condition that poses an additional risk to the patient (i.e. haemoptysis, non-healing, bone fracture, wound/ulcer) - Low probability of treatment compliance - Any uncontrolled medical condition that poses an additional risk to the patient - Planned immunisation with live vaccine

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02308527
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of Birmingham
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Lucas Moreno, MD
Principal Investigator Affiliation University of Birmingham
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherOtherIndustryOtherOther
Overall Status Recruiting
Countries Austria, Belgium, Denmark, France, Ireland, Italy, Netherlands, Spain, Switzerland, United Kingdom
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Neuroblastoma
Additional Details

This is an international open-label, randomised, multicentre phase II trial of temozolomide ± irinotecan, with or without bevacizumab, for the treatment of patients with relapsed or refractory neuroblastoma. The study will evaluate the safety and activity of these combinations. Patients will be registered into the trial and randomised at the same time to one of the following two arms (approximately 30 patients per arm): TTo: Temozolomide + Topotecan dBTTo: Dinuximab beta + Temozolomide + Topotecan Arms which have now closed to recruitment: dBT: Dinutuximab beat + Temozolomide Closed 28 ]Jan 2020 T: Temozolomide

  • - Closed 28 Jan 2020 BT: Bevacizumab + Temozolomide - Closed 7 Feb 2019 IT: Irinotecan + Temozolomide - Closed 21 June 2018 BIT: Bevacizumab + Irinotecan + Temozolomide - Closed 21 June 2018 BTTo: Bevacizumab + Temozolomide + Topotecan - Closed 7 Feb 2019 Randomisation will be via a secure on-line computer-based system at the Cancer Research Clinical Trial Unit (CRCTU), University of Birmingham, United Kingdom (UK) and patients will be allocated in a 2:1 ratio.
Minimisation will be used to ensure balance across the arms for the important prognostic factors as described by London et al. [10]: a) relapsed, refractory disease, b) early (< 18 months), late relapse (≥18 months) and c) measurable versus evaluable disease (i.e. disease evaluated according to RECIST versus disease detectable only by MIBG scanning with or without bone marrow involvement as detected by local morphology) Patients will receive treatment for 6 courses, lasting 24 weeks. Patients with a response (CR, PR) or stable disease (SD) while on the BEACON-Neuroblastoma trial will receive 6 cycles of trial treatment. If the patient has achieved a satisfactory response (i.e. CR, PR or SD) with acceptable toxicity, treatment may be extended beyond 6 cycles (up to 12 cycles) after discussion with the Sponsor and the Chief Investigator (CI). In addition, patients randomised to TTo may recieve an optional regimen of dinutuximab beta + topotecan + cyclophosphamide (up to 6 cycles).

Arms & Interventions

Arms

Active Comparator: Temozolomide

Temozolomide Days 1-5 every 4 weeks

Experimental: Bevacizumab + Temozolomide

Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks

Experimental: Irinotecan + Temozolomide

Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks

Experimental: Bevacizumab + Irinotecan + Temozolomide

Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks

Experimental: Temozolomide + Topotecan

Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks

Experimental: Bevacizumab + Temozolomide + Topotecan

Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks

Experimental: Dinutuximab beta + Temozolomide

Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks

Experimental: Dinutuximab beta + Temozolomide + Topotecan

Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks

Other: Dinutuximab beta + Topotecan + Cyclophosphamide

Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks

Interventions

Drug: - Bevacizumab

10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression

Drug: - Temozolomide

200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Drug: - Temozolomide

100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Drug: - Irinotecan

50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression

Drug: - Bevacizumab

15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression

Drug: - Topotecan

0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression

Drug: - Temozolomide

150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Drug: - Dinutuximab Beta

10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression

Drug: - Cyclophosphamide

250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Vienna, Austria

Status

Recruiting

Address

St Anna Children's Hospital and CCRI/Studies and Statistics

Vienna, , A-1090

Site Contact

Ruth Ladenstein, MD

ruth.ladenstein@ccri.at

43 1 40470 4750

University Hospital, Gent, Belgium

Status

Recruiting

Address

University Hospital

Gent, ,

Site Contact

Genevieve Laureys, MD

genevieve.laureys@uzgent.be

0121 4143788

University Hospital Rigshospitalet, Copenhagen, Denmark

Status

Recruiting

Address

University Hospital Rigshospitalet

Copenhagen, , DK-2100

Site Contact

Karsten Nysom, MD

Karsten.Nysom@regionh.dk

45 35 45 08 09

Hopital des Enfants, Toulouse, France

Status

Recruiting

Address

Hopital des Enfants

Toulouse, , 31059

Site Contact

Marion Gambart, MD

gambart.m@chu-toulouse.fr

33 534 55 86 11

Our Ladys Children's Hospital Dublin, Dublin, Ireland

Status

Recruiting

Address

Our Ladys Children's Hospital Dublin

Dublin, , Dublin 12

Site Contact

Cormac Owens, MD

cormac.owens@olchc.ie

35 31 409 6659

Ospedale Pediatrico Bambino Gseu, Rome, Italy

Status

Recruiting

Address

Ospedale Pediatrico Bambino Gseu

Rome, , 00165

Site Contact

Aurora Castellano, MD

aurora.castellano@opbg.net

0121 4143788

Princess Maxima Centre, Utrecht, Netherlands

Status

Recruiting

Address

Princess Maxima Centre

Utrecht, ,

Site Contact

Michel Zwaan, MD

c.m.zwaan@prinsesmaximacentrum.nl

0121 4143788

Instituto de Investigacion Sanitaria, Valencia, Spain

Status

Recruiting

Address

Instituto de Investigacion Sanitaria

Valencia, , 46026

Site Contact

Victoria Castel, MD

castel_vic@gva.es

34 963 862 758

Swiss Paediatric Oncology Group, Bern, Switzerland

Status

Recruiting

Address

Swiss Paediatric Oncology Group

Bern, , 3008

Sutton, Surrey, United Kingdom

Status

Recruiting

Address

The Royal Marsden NHS Foundation Trust and Institute of Cancer Research

Sutton, Surrey, SM2 5PT

Site Contact

Sucheta Vaidya, MD

sucheta.vaidya@icr.ac.uk

0121 4143788

The content provided by NBTS on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to: Terms, Conditions & Privacy